Limited role for ivabradine in the treatment of chronic heart failure

Heart

Volumn 97, Issue 23, 2011, Pages 1961-1966

  Cullington, Damien ^a   Goode, Kevin M ^a   Cleland, John G F ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ATENOLOL; BISOPROLOL; CARVEDILOL; CELIPROLOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; LOOP DIURETIC AGENT; METOPROLOL; NEBIVOLOL; PROPRANOLOL; SOTALOL; STATIN; TIMOLOL; WARFARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINUS RHYTHM; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ARRHYTHMIAS, CARDIAC; BENZAZEPINES; CARDIOTONIC AGENTS; CHRONIC DISEASE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 80655124547     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300041     Document Type: Article

References (37)

1. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiological studies. Am J Epidemiol 1980;112:737-49.
2. Kristal-Boneh E, Silber H, Harari G, et al. The association of resting heart rate with cardiovascular, cancer and all cause mortality. Eight year follow-up of 3527 male Israli employees (the CORDIS Study). Eur Heart J 2000;21:116-24. (Pubitemid 30072626)
3. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-74. (Pubitemid 40695027)
4. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolopril STudy (INVEST). Eur Heart J 2008;29:1327-34. (Pubitemid 351768127)
5. Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortlality in elderly subjects with systolic hypertension. Arch Intern Med 2002;162:2313-21. (Pubitemid 35332514)
6. Poole-Wilson PA, Uretsky BF, Thygesen K, et al. Mode of death in heart failure: findings from the ATLAS trial. Heart 2003;89:42-8. (Pubitemid 36044288)
7. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
8. Nagale H, Rodiger W, Castel MA. Rate-responsive pacing in patients with heart failure: long term results of a randomised study. Europace 2008;10:1182-8.
9. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823-30. (Pubitemid 47277500)
10. Ahmandi-Kashani M, Kessler DJ, Day J, et al. Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation 2009;120:2040-5.
11. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double blind, placebo-controlled trial. Lancet 2008;372:807-16.
12. Swedberg K, Komajda M, Bohm M, et al. Rationale and design of a randomised, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with If Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75-81.
13. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J 1999;1(Suppl H):H64-9. (Pubitemid 29304286)
14. McAlister FA, Wiebe N, Ezekowitz JA, et al. Meta-analysis: β-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Inter Med 2009;150:784-94.
15. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43Fe9F.
16. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta regression of randomised clinical trials. Eur Heart J 2007;28:3012-19. (Pubitemid 350262265)
17. Flannery G. Analysis of randomised controlled trials on the effect of magnitude of heart rate reduction of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008;101:865-9.
18. Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006;152:e9-13.
19. Logeart D, Gueffet JP, Rouzet F, et al. Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a pilot study. Eur J Heart Fail 2009;11:53-7.
20. Borer JS. Drug insight: if inhibitors as specific heart rate reducing agents. Nat Clin Pract Cardiovasc Med 2004;1:103-9. (Pubitemid 40823707)
21. Verkerk AO, van Ginneken AC, Wilders R. Pacemaker activity of the human sinoatrial node: role of the hyperpolarization-activated current, I(f). Int J Cardiol 2009;132:318-36.
22. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
23. National Institute for Health and Clinical Excellence. Chronic Heart Failure (CG108). Management of Chronic Heart Failure in Adults in Primary and Secondary Care, 2010. http://www.nice.org.uk/CG108.
24. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89.
25. López-Sendón J, Swedberg K, McMurray J, et al. The Task Force on Beta Blockers of the European Society of Cardiology. Expert consensus document on betaadrenergic receptor blockers. Eur Heart J 2004;25:1341-62.
26. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. (Pubitemid 36835815)
27. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55. (Pubitemid 26152713)
28. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
29. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
30. Flather MD, Shibata MC, Coats AJ, et al. Randomised trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. (Pubitemid 40222359)
31. Ambrosio G, Flather MD, Bohm M, et al. β-Blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart 2011;97:209-14.
32. Cleland JG, MacDonagh T, Rigby AS, et al. The national heart failure audit for England and Wales 2008-2009. Heart 2010;97:876-86.
33. Report NHFA. Report for the Audit Period Between April 2009 and March 2010. 2010. http://www.ic.nhs.uk (accessed May 2011).
34. Hawkins NM, MacDonald MR, Petrie MC, et al. Bioprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomised controlled trial. Eur J Heart Fail 2009;11:684-90.
35. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Eur Heart J 2003;24:464-74. (Pubitemid 36286188)
36. Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl 2009;11(Suppl A):A21-5.
37. Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta blocker therapy for patients with heart failure: a quantitative review of randomised trials. Arch Intern Med 2004;164:1389-94. (Pubitemid 38937849)